Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary - Preliminary - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Leukemia - CALGB-10502
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-19808
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary - Primary - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010 Abstract - No-Endpoint - Comprehensive - Leukemia - CALGB-10503
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary - Primary - Leukemia - CALGB-10503
Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011 Abstract - Primary - Comprehensive - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621
MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-xxpressed with its host gene and independently impacts on the clinical outcome of older patients (pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Maharry, K. , Schwind, S. ... - - Blood - 2011 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9420 , CALGB-9720
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808 Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007 Abstract - Primary - Preliminary - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665
Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study Langer, C. , Maharry, K. S. , Mrozek, K. A. , Paschka, P. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-9621
High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study Langer, C. , Ruppert, A. S. , Radmacher, M. D. , Whitman, S. P. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts) Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Paschka, P. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20202 , CALGB-9621
High ERG expression levels predict adverse outcome and refine molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study Marcucci, G. , Maharry, K. S. , Whitman, S. P. , Vukosavljevic, T. ... - AACR - AACR Annual Meeting - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study Marcucci, G. , Maharry, K. S. , Wu, Y. , Radmacher, M. D. ... - - Haematologica - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study Marcucci, G. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20205 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old Marcucci, G. , Moser, B. K. , Blum, W. G. , Stock, W. , Wetzler, M. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Leukemia - CALGB-10201
Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures Mendler, J. H. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2011 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9720
ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category Metzeler, K. H. , Becker, H. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2011 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-20202 , CALGB-8461 , CALGB-9665
TET2 mutations occur in over 20% of adults with de novo cytogenetically normal AML, and their prevalence increases with age: A Cancer and Leukemia Goup B study. Metzeler, K. H. , Maharry, K. , Margeson, D. , Curfman, J. ... - - Haematologica - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study Metzeler, K. H. , Maharry, K. , Radmacher, M. D. , Mrozek, K. ... - - Blood - 2010 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , C8641 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes in Adults: a Cancer and Leukemia Group B (CALGB) Study Mrozek, K. , Holland, K. B. , Pettenati, M. J. , Maharry, K. ... - ASH - Blood - 2009 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - Comprehensive
Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts) Mrozek, K. , Marcucci, G. , Maharry, K. , Nicolet, D. , Becker, H. ... - - Blood - 2011 Abstract - Secondary - Primary - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
High expression of DNMT3B negatively impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid leukemia (AML) [CALGB 20202 (Alliance)]. Niederwieser, C. , Kohlschmidt, J. , Maharry, K. , Mrózek, K. ... - EHA - European Hematology Association Congress - 2013 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-20202
Prognostic impact of NPM1 mutations in cytogenetically normal (CN) acute myeloid leukemia (AML) is adversely affected by high expression of the ERG gene: A Cancer and Leukemia Group B (CALGB) study Paschka, P. , Marcucci, G. , Maharry, K. S. , Whitman, S. P. ... - EHA - Haematol-Hematol J - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study Paschka, P. , Marcucci, G. , Ruppert, A. S. , Mrozek, K. ... - - Blood - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study Radmacher, M. D. , Marcucci, G. , Paschka, P. , Vukosavljevic, T. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML) Schwind, S. , Marcucci, G. , Maharry, K. S. , Radmacher, M. D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Leuk Corr Sci - C9621 , CALGB-19808
Improved clinical outcome of cytogenetically normal acute myeloid leukemia patients with the MLL partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study Whitman, S. P. , Ruppert, A. S. , Marcucci, G. , Mrozek, K. A. ... - - Cancer Res. - 2007 Abstract - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665 , CALGB-9769
FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study Whitman, S. P. , Ruppert, A. S. , Radmacher, M. D. , Mrozek, K. A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) Whitman, S. , Kohlschmidt, J. , Maharry, K. , Nicolet, D. ... - - Blood - 2012 Abstract - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9665 , CALGB-20202
